Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NF-κB inhibitor in mice and rats by LC-MS/MS

Biomedical Chromatography

Volumn 27, Issue 7, 2013, Pages 900-909

  Gautam, Nagsen ^a   Bathena, Sai Praneeth R ^a   Chen, Qianyi ^b   Natarajan, Amarnath ^b   Alnouti, Yazen ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

LC MS MS; Metabolism; NF B inhibitor 13 197; Pharmacokinetics; Protein binding

Indexed keywords

BIOCHEMISTRY; BODY FLUIDS; METABOLITES; PHARMACOKINETICS; PHYSIOLOGY; PROTEINS; RATS; TISSUE; UREA;

EFFICACY DATA; IN-VITRO; LC-MS-MS; LC.MS/MS; MICE PLASMA; NF-ΚB INHIBITOR 13-197; PANCREATIC CANCERS; PROTEIN METABOLISM; PROTEIN-BINDING; QUINOXALINES;

METABOLISM;

13 197; I KAPPA B KINASE INHIBITOR; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; HEART; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; LUNG; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RAT; SPLEEN; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

MUS; RATTUS;

EID: 84878996440     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2880     Document Type: Article

References (20)

1. Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, Baba Y and Kumar A. Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian Journal of Experimental Biology 2004; 42: 341-353.
2. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual Reviews in Immunology 1996; 14: 649-683.
3. Cheng A, Diller DJ, Dixon SL, Egan WJ, Lauri G and Merz KM Jr. Computation of the physio-chemical properties and data mining of large molecular collections. Journal of Computer Chemistry 2002; 23: 172-183.
4. Clark DE and Grootenhuis PD. Progress in computational methods for the prediction of ADMET properties. Current Opinions on Drug Discovery and Development 2002; 5: 382-390.
5. el-Kamar FG, Grossbard ML and Kozuch PS. Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. The Oncologist 2003; 8: 18-34.
6. Farrow B and Evers BM. Inflammation and the development of pancreatic cancer. Surgical Oncology 2002; 10: 153-169.
7. Holcomb B, Yip-Schneider M and Schmidt CM. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008; 36: 225-235.
8. Huang J, Bathena SP and Alnouti Y. Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer. Drug Metabolism and Pharmacokinetics 2010; 25: 487-499.
9. Huang J, Hu L, Xu L, Sun M, Fan Z, Qiu J, Li G and Si L. In vitro enantioselective metabolism of TJ0711 hydrochloride by human liver microsomes using a novel chiral liquid chromatography-tandem mass spectrometry method. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2012; 891-892: 98-101.
10. Ji Z, Mei FC, Xie J and Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. Journal of Biological Chemistry 2007; 282: 14048-14055.
11. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Research 2007; 67: 3853-3861.
12. Kwok BH, Koh B, Ndubuisi MI, Elofsson M and Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chemical Biology 2001; 8: 759-766.
13. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition 1995; 23: 1008-1021.
14. Roos A and Hinderling PH. Protein binding and erythrocyte partitioning of the antirheumatic proquazone. Journal of Pharmaceutical Science 1981; 70: 252-257.
15. Schuhmacher J, Buhner K and Witt-Laido A. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. Journal of Pharmaceutical Science 2000; 89: 1008-1021.
16. Schuhmacher J, Kohlsdorfer C, Buhner K, Brandenburger T and Kruk R. High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. Journal of Pharmaceutical Science 2004; 93: 816-830.
17. Sen R and Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-928.
18. Wang Y, Roy A, Sun L and Lau CE. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metabolism and Disposition 1999; 27: 855-859.
19. Yuan J, Yang DC, Birkmeier J and Stolzenbach J. Determination of protein binding by in vitro charcoal adsorption. Journal of Pharmacokinetics and Biopharmaceutics 1995; 23: 41-55.
20. Zheng YT, Zhu JH, Ma G, Zhu Q, Yang P, Tan B, Zhang JL, Shen HX, Xu JL, Zhu YZ and Cai WM. Preclinical assessment of the distribution, metabolism, and excretion of S-propargyl-cysteine, a novel H2S donor, in Sprague-Dawley rats. Acta Pharmacologica Sinica 2012; 33: 839-844.